Search

Displaying results 3301 - 3310 of 8196 in total
  1. Drug

    Flavin adenine dinucleotide

    go.drugbank.com/drugs/DB03147
    Approved

    The coenzyme of various aerobic dehydrogenases, e.g., D-amino acid oxidase and L-amino acid oxidase. … (Lehninger, Principles of Biochemistry, 1982, p972) Flavin adenine dinucleotide is approved for use in Japan under the trade name Adeflavin as an ophthalmic treatment for vitamin B2 deficiency.

  2. Drug

    Bithionol

    go.drugbank.com/drugs/DB04813
    ApprovedWithdrawn

    Bithionol, formerly marketed as an active ingredient in various topical drug products, was shown to be a potent photosensitizer with the potential to cause serious skin disorders.

  3. Drug

    Loprazolam

    go.drugbank.com/drugs/DB13643
    Experimental

    It is not an FDA-approved drug. … Loprazolam is recommended as a short-term therapy only, due to adverse events associated with the drug including dependence and withdrawal symptoms.

  4. Drug

    Gemeprost

    go.drugbank.com/drugs/DB08964
    ApprovedWithdrawn

    Gemeprost is a prostaglandin E1 (PGE1) analog and antiprogestogen used for preoperative dilation of the cervix before surgical abortion. It is available as vaginal suppositories and also used in combination with the antiprogestin and mif...

  5. Drug

    Sodium phosphate, monobasic, unspecified form

    go.drugbank.com/drugs/DB14503
    Approved

  6. Drug

    Cyamemazine

    go.drugbank.com/drugs/DB09000
    Experimental

    Cyamemazine actually behaves like an atypical antipsychotic, due to its potent anxiolytic effects (5-HT2C) and lack of extrapyramidal side effects (5-HT2A).

  7. Drug

    Pipequaline

    go.drugbank.com/drugs/DB13991
    Experimental

    Due to these differences, this drug is classified as a nonbenzodiazepine anxiolytic. … Pipequaline is an anticonflict & anticonvulsant quinoline derivative. It is an anxiolytic drug that was never marketed.

  8. Drug

    Remibrutinib

    go.drugbank.com/drugs/DB16852
    ApprovedInvestigational

    Remibrutinib is a selective Bruton's tyrosine kinase inhibitor. The FDA approved remibrutinib on September 30, 2025 as the only oral, targeted treatment for chronic spontaneous urticaria. Bruton's tyrosine kinase plays a role in B cell r...

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  9. Drug

    Bisegliptin

    go.drugbank.com/drugs/DB06127
    Investigational

    It is an orally active, dipeptidyl peptidase-IV (DPPIV) inhibitor which lowers blood glucose levels by blocking the degradation of the hormone GLP-1 thereby stimulating glucose-dependent insulin secretion

  10. Drug

    Huperzine A

    go.drugbank.com/drugs/DB04864
    ApprovedInvestigationalWithdrawn

    Huperzine A, is a naturally occurring sesquiterpene alkaloid found in the extracts of the firmoss Huperzia serrata. The botanical has been used in China for centuries for the treatment of swelling, fever and blood disorders. Recently in ...